Therapy for Pediatric Hodgkin Lymphoma

Trial ID or NCT#

NCT00145600

Status

not recruiting iconNOT RECRUITING

Purpose

With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.

Official Title

Risk-Adapted Therapy for Pediatric Hodgkin's Disease

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michael Link

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535